Management of toxic optic neuropathy via a combination of Wharton’s jelly-derived mesenchymal stem cells with electromagnetic stimulation

Table 4 Statistical comparison of measurements according to groups

Measurements	Group			pG1	pG2	pG3
	Group1	Group2	Group3
	X ± s.s	X ± s.s	X ± s.s
BCVA before	48.08 ± 18.44	50.33 ± 18.58	48.25 ± 12.26	0.01*	0.03*	0.02*
BCVA after	70.83 ± 25.84	60.92 ± 21.93	63.67 ± 16.33	0.01*	0.03*	0.02*
Visual field FPDI before	21.33 ± 18.14	24.67 ± 21.12	31.08 ± 16.81	0.01*	0.02*	0.04*
Visual field FPDI after	41.67 ± 32.29	32.92 ± 27.31	39.33 ± 20.31	0.01*	0.02*	0.04*
GCC thickness	78.42 ± 17.99	77.17 ± 18.77	78.67 ± 11.16	0.01*	0.04*	0.02*
GCC thickness	61.83 ± 12.47	67.25 ± 17.41	67.25 ± 9.54	0.01*	0.04*	0.02*
VEP P100 lat. before	145.33 ± 7.56	143.75 ± 8.95	146.5 ± 6.4	0.01*	0.03*	0.02*
VEP P100 lat. after	118.92 ± 12.03	131.92 ± 15.67	131.75 ± 13.73	0.01*	0.03*	0.02*
VEP P100 ampl before	2.16 ± 0.94	2.32 ± 0.91	2.13 ± 0.68	0.01*	0.04*	0.01*
VEP P100 ampl after	4.42 ± 1.79	2.88 ± 1.24	3.88 ± 1.14	0.01*	0.04*	0.01*

**Mann Whitney U test, *p < 0.05: statistically signifficant
BCVA best corrected visual acuity, (ETDRS letters), FPDI fundus perimetry deviation index (%), GCC thickness Ganglion cell complex (µm), VEP Visual evoked potential, P100 lat latency (ms), P100 ampl amplitude (mV)

ISSN: 1757-6512